Sol-Gel Technologies, listed on NASDAQ under the ticker SLGL, has received a significant upgrade from HC Wainwright, which raised its target price from $6.00 to $50.00. This adjustment, announced in a research note on Monday, comes alongside a maintained “buy” rating for the stock, indicating strong investor confidence in the company’s future performance.
In addition to the target price increase, HC Wainwright provided earnings estimates for Sol-Gel Technologies for the upcoming quarters. The firm anticipates a loss of $2.09 per share for Q3 2025, followed by a modest profit of $0.40 per share in Q4 2025. The annual earnings expectations for 2025 stand at a projected loss of $0.68 per share. Looking further ahead, losses for Q1 2026 are estimated at $1.63 per share, with subsequent quarters showing a gradual increase in losses, totaling $6.60 for the fiscal year 2026.
The stock’s recent performance has attracted attention from several brokerage firms. Weiss Ratings reaffirmed a “hold (c-)” rating for Sol-Gel Technologies on October 8, 2023, while Wall Street Zen upgraded the stock to a “buy” on September 13, 2023. Currently, the consensus rating among analysts is “Moderate Buy,” with an average target price of $50.00, according to MarketBeat.com.
Recent Earnings Report Highlights Strong Performance
Sol-Gel Technologies recently reported its quarterly earnings on August 15, 2023. The company achieved earnings of $4.17 per share, significantly exceeding the consensus estimate of a loss of $0.67 per share by a remarkable $4.84. The company’s revenue for the quarter reached $17.26 million, far surpassing analyst projections of $2.86 million. Despite these strong figures, Sol-Gel Technologies recorded a negative return on equity of 11.80% and a net margin of 14.25%.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd. operates in Israel, focusing on developing topical dermatological treatments for patients with severe skin conditions. The company offers products such as Twyneo, a once-daily, non-antibiotic topical cream for treating acne vulgaris, and Epsolay, a cream designed for the treatment of papulopustular (subtype II) rosacea.
With a marked increase in its target price and positive earnings performance, Sol-Gel Technologies is positioning itself as a notable player in the dermatological market. Investors and analysts alike will be keen to track the company’s progress as it navigates upcoming fiscal challenges and opportunities.
